A Review of Novel Therapies for Melanoma

@article{Karimkhani2014ARO,
  title={A Review of Novel Therapies for Melanoma},
  author={C. Karimkhani and R. Gonz{\'a}lez and R. Dellavalle},
  journal={American Journal of Clinical Dermatology},
  year={2014},
  volume={15},
  pages={323-337}
}
  • C. Karimkhani, R. González, R. Dellavalle
  • Published 2014
  • Medicine
  • American Journal of Clinical Dermatology
  • This review summarizes results from major recent trials regarding novel therapeutic agents in melanoma. The topics discussed include targeted therapy with BRAF (V-RAF murine sarcoma viral oncogene homolog B) inhibitors (vemurafenib and dabrafenib), MEK (mitogen-activated protein kinase kinase) inhibitors (trametinib), bcr-abl/c-kit/PDGF-R inhibitors (imatinib), and angiogenesis inhibitors (bevacizumab and aflibercept), as well as immunotherapy with anti-CTLA-4 (anti-cytotoxic T-lymphocyte… CONTINUE READING
    Cancer treatment and survivorship statistics, 2016
    • 2,671
    • PDF
    Immune-mediated Adverse Effects of Anti-CTLA-4 Antibody Therapy in Metastatic Melanoma
    • 2015
    Pembrolizumab: First Global Approval
    • 67
    Pembrolizumab: A Review in Advanced Melanoma
    • 30
    • Highly Influenced
    New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging.
    • 24
    • PDF

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 79 REFERENCES
    Improved survival with ipilimumab in patients with metastatic melanoma.
    • 10,412
    • Highly Influential
    • PDF
    Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
    • 8,126
    • PDF
    The blockade of immune checkpoints in cancer immunotherapy
    • 6,598
    • PDF
    Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
    • 2,673
    • PDF
    Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
    • 2,055
    • Highly Influential
    • PDF
    Nivolumab plus ipilimumab in advanced melanoma.
    • 3,152
    • PDF
    Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
    • 2,318
    • PDF
    Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
    • 1,785
    • PDF